Effect of MD1003 in progressive multiple sclerosis with walking impair

Main measures

• Primary efficacy endpoint:

• Results

  Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.

  Lancet Neurol · 2020

• Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brai

  Phase 2 · Running, not recruiting

  Still running

• Testing and comparing multiple drugs at once against the standard trea

  Phase 3 · Ongoing (inferred)

  Still running

• Metformin Treatment in Progressive Multiple Sclerosis

  Early phase 1 · Completed

  Paper found, not read

• Neuroprotection With N-acetyl Cysteine for Patients With Progressive M

  Phase 2 · Running, not recruiting

  Still running

• Lipoic Acid for Progressive Multiple Sclerosis (MS)

  Phase 2 · Completed

  Missed its main goal

• A Trial of Bile Acid Supplementation in Patients With Multiple Scleros

  Phase 1 / Phase 2 · Completed

  Results posted, not judged

1. Oct 2026In scope changed from true to false

1. Started

   Nov 2016